CPA
SLNO

Capital Performance Advisors’s Soleno Therapeutics SLNO Stock Holding History

Capital Performance Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17
Closed -$858 – 2279
2024
Q3 		$858 Buy
+17
New +$814 ﹤0.01% 1975

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital Performance Advisors's SLNO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Soleno Therapeutics (SLNO) in Q4 2024, closing a stake of 17 shares — an estimated $858 sold.

Capital Performance Advisors first reported a position in SLNO in Q3 2024 and held it in 1 quarter. The position peaked at $858 in Q3 2024. 166 funds tracked by Wall St. Rank hold SLNO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Soleno Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 17 Soleno Therapeutics shares in Q4 2024, an estimated $858.
  • Capital Performance Advisors first reported a position in Soleno Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Soleno Therapeutics position peaked at $858 in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.